Table 2 Base-case analysis in adults aged 40–49 years.
Strategy | Total | Incremental | ICER | |||||
|---|---|---|---|---|---|---|---|---|
Cost ($) | QALYs | LYs | Cost ($) | QALYs | LYs | ($/QALY) | ($/LY) | |
Liver disease only | ||||||||
Screening | 13,061 | 15.7087 | 18.6143 | 2001 | 0.0193 | 0.0172 | 103,405 | 116,400 |
No screening | 11,060 | 15.6894 | 18.5971 | |||||
Liver disease and CVD | ||||||||
Screening | 26,950 | 15.0982 | 17.9308 | 1878 | 0.0252 | 0.0245 | 74,596 | 76,771 |
No screening | 25,072 | 15.073 | 17.9063 | |||||
Liver disease, CVD and extrahepatic malignancy | ||||||||
Screening | 36,210 | 14.7949 | 17.7989 | 1727 | 0.0257 | 0.0243 | 67,135 | 70,912 |
No screening | 34,483 | 14.7691 | 17.7746 | |||||
